Minocycline affects the expression of glial cell derived neurotrophic factor family in a rat model of Parkinson’s disease

Xing Hong-xia; Jiang Jian-kai; Qin Li-yuan; Wang Yu-mei

doi:10.3969/j.issn.2095-4344.2016.27.010

Abstract：BACKGROUND:Researches have found that minocycline plays a neuroprotective effect by inhibiting the microgliacel proliferation and activation and suppressing glial cels to release cytokines and chemokines. OBJECTIVE:To investigate the influence of minocycline on glial cel line derived neurotrophic factor, NTN and gene expression in substantia nigra and corpus striatum in Parkinson’s disease model rats. <br> METHODS:144 rats were randomly divided into four groups, with 36 rats in each group. In the normal control group, no intervention was given. In the model and experimental groups, 6-hydroxydopamine was injectedin the right substantia nigra pars compacta and ventral tegmental area to establish Parkinson’s disease models. In the sham surgery group, vitamin C was injected in the two points. In the experimental group, after model establishment, rats were intragastricaly given 4.5 g/L minocycline 45 mg/kg. From then on, additional 22.5 mg/kg minocycline was added every 12 hours. The last group was normal control group. Immediately, 12 hours, 1, 7, 14 and 21 days after model induction, SP immunohistochemistry was used to detect the expression of glial cel line derived neurotrophic factor and NTN expression in the substantia nigra and corpus striatum. RT-PCR was used to identify glial cel line derived neurotrophic factor and NTN mRNA expression in the substantia nigra and corpus striatum. <br> RESULTS AND CONCLUSION:Both in the substantia nigra and corpus striatum, the positive cel number and relative gene expression of glial cel line derived neurotrophic factor and NTN were lower in the model group than in the normalcontrol and sham surgery groups (P< 0.05). Glial cel line derived neurotrophic factor-and NTN-positive cel number and relative expression were higher in the experimental group than in the model group (P< 0.05). These findings suggest that minocyclinecan delay the process of Parkinson’s disease pathogenesis by promoting glial cel line derived neurotrophic factor protein and gene expression.